Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15633193 | 0.76 | — | — | |
| SCHEMBL21995020 | 0.73 | SLC6A3 (0.38) | RBP4MAPK1KDM4EALDH1A1 | |
| SCHEMBL31644564 | 0.70 | SMN1; SMN2 (0.49) | MAPK1ALDH1A1 | |
| SCHEMBL71485 | 0.70 | KMO (0.42) | RBP4KDM4E | |
| Hydrochloric Acid SCHEMBL73025 | 0.69 | KMO (0.41) | RBP4KDM4E | |
| SCHEMBL24386910 | 0.68 | NOTUM (0.43) | GAAMAPK1KDM4EALDH1A1 | |
| SCHEMBL73024 | 0.68 | PTGDR2 (0.36) | ALDH1A1 | |
| SCHEMBL18432646 | 0.68 | SLC6A3 (0.37) | CNR2GAAKDM4EALDH1A1 | |
| SCHEMBL17535506 | 0.68 | GAA (0.40) | GAAKDM4EALDH1A1 | |
| SCHEMBL17773644 | 0.67 | MAPK1 (0.39) | GAAMAPK1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3656384-B1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3656384-B1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3656384-A1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME CORP. (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3656384-A1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME CORP. (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3295942-B1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3295942-B1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10189831-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189831-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3295942-A1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME CORP. (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-3295942-A1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME CORP. (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9718819-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9469634-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469634-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469634-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160145255-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160145255-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160145255-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
| EP-2903977-A1 | 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014058747-A1 | 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-04-17 | — | — | WO | disclosed |
| US-20140100231-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145255-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR2E, RTF1 | CNR2 4871/4885CNR1 4659/4885RBP4 1418/4885 |
| US-20140100231-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR2E, RTF1 | CNR2 4871/4885CNR1 4659/4885RBP4 1418/4885 |
| US-10189831-B2 | Non-nucleoside reverse transcriptase inhibitors | POLRMT, POLR2E, RTF1 | CNR2 4871/4885CNR1 4659/4885RBP4 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.